Cassava Sciences Gelecekteki Büyüme

NasdaqCM:SAVA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	N/A	5	N/A	N/A	1
12/31/2025	N/A	-21	N/A	N/A	2
12/31/2024	N/A	-29	N/A	N/A	2
9/30/2024	N/A	-18	-78	-78	N/A
6/30/2024	N/A	-15	-86	-86	N/A
3/31/2024	N/A	-48	-88	-88	N/A
12/31/2023	N/A	-97	-82	-82	N/A
9/30/2023	N/A	-95	-81	-81	N/A
6/30/2023	N/A	-90	-77	-76	N/A
3/31/2023	N/A	-83	-70	-67	N/A
12/31/2022	N/A	-76	-80	-78	N/A
9/30/2022	N/A	-71	-67	-64	N/A
6/30/2022	N/A	-61	-81	-57	N/A
3/31/2022	N/A	-46	-74	-51	N/A
12/31/2021	N/A	-32	-52	-30	N/A
9/30/2021	N/A	-21	-45	-23	N/A
6/30/2021	N/A	-13	-11	-11	N/A
3/31/2021	N/A	-9	-6	-6	N/A
12/31/2020	N/A	-6	-5	-5	N/A
9/30/2020	N/A	-5	-5	-5	N/A
6/30/2020	N/A	-4	-3	-3	N/A
3/31/2020	N/A	-4	-3	-3	N/A
12/31/2019	N/A	-5	-3	-3	N/A
9/30/2019	N/A	-4	-3	-2	N/A
6/30/2019	N/A	-4	-3	-3	N/A
3/31/2019	N/A	-6	-4	-4	N/A
12/31/2018	N/A	-7	-5	-5	N/A
9/30/2018	N/A	-8	-6	-6	N/A
6/30/2018	N/A	-10	N/A	-6	N/A
3/31/2018	N/A	-11	N/A	-8	N/A
12/31/2017	N/A	-12	N/A	-8	N/A
9/30/2017	N/A	-12	N/A	-10	N/A
6/30/2017	N/A	-13	N/A	-10	N/A
3/31/2017	N/A	-12	N/A	-11	N/A
12/31/2016	N/A	-15	N/A	-12	N/A
9/30/2016	N/A	-17	N/A	-13	N/A
6/30/2016	N/A	-17	N/A	-12	N/A
3/31/2016	N/A	-17	N/A	-11	N/A
12/31/2015	N/A	-14	N/A	-9	N/A
9/30/2015	N/A	-12	N/A	-8	N/A
6/30/2015	N/A	-12	N/A	-7	N/A
3/31/2015	N/A	-12	N/A	-8	N/A
12/31/2014	N/A	-12	N/A	-10	N/A
9/30/2014	35	23	N/A	-8	N/A
6/30/2014	37	26	N/A	-9	N/A
3/31/2014	39	29	N/A	-8	N/A
12/31/2013	41	32	N/A	-7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SAVA önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: SAVA önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: SAVA önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: SAVA şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: SAVA gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SAVA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Cassava Sciences Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates upgraded to US$0.77 loss

Forecast to breakeven in 2023

Price target increased to US$84.00

Price target decreased to US$58.67

Forecast to breakeven in 2022

Recent updates

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh

Cassava Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer

New minor risk - Profitability

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Announces Demise of Sanford Robertson, Board Member

Cassava Sciences, Inc. Announces Expansion of Open-Label Extension Trials

Cassava Sciences: Turning The Corner Into A Brick Wall

Cassava Sciences, Inc. Announces Chief Executive Officer Changes

New minor risk - Profitability

New major risk - Revenue and earnings growth

New minor risk - Profitability

Independent Director exercised options to buy US$3.9m worth of stock.

Cassava Sciences, Inc., Annual General Meeting, May 09, 2024

Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer’s Disease Dementia

Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index

Cassava Sciences, Inc. Announces Board Appointments

New major risk - Revenue and earnings growth

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’S Disease

Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer’s Disease

Independent Director recently bought US$308k worth of stock

New major risk - Revenue and earnings growth

Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging

Founder exercised options and sold US$480k worth of stock

Lead Independent Director exercised options to buy US$259k worth of stock.

Independent Director recently bought US$2.3m worth of stock

Consensus EPS estimates upgraded to US$0.77 loss

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Forecast to breakeven in 2023

Cassava Sciences, Inc. Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Price target increased to US$84.00

Cassava Sciences, Inc. Announces Executive Changes

Cassava Sciences, Inc. Announces Completion of Dosing in Open-Label Study of Simufilam for Alzheimer’s Disease

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Cassava Sciences, Inc. Appoints Christopher Cook as Senior Vice President and General Counsel

Cassava Sciences Announces Initiation of an Open-Label Extension Study

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Cassava Sciences: Trying To Manage Expectations

Lead Independent Director exercised options to buy US$86k worth of stock.

Cassava Sciences reaches over five-month high on rising volumes

Cassava Sciences Looks As Good Of A Purchase As Ever

Cassava Sciences stock jumps 10% after director buys $860K shares

Chief Clinical Development Officer recently bought US$61k worth of stock

Lead Independent Director recently bought US$2.1m worth of stock

Cassava Sciences rally continues as stock up 39%

Price target decreased to US$58.67

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Founder exercised options and sold US$249k worth of stock

Chief Medical Officer & Director exercised options and sold US$81k worth of stock

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

Founder exercised options to buy US$1.0m worth of stock.

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

3 Key Points To Remember About Cassava Sciences